Skip to content

Effectiveness of Oxitard capsule and Immusante tablet towards early stages of Oral Submucous Fibrosis.

Comparative efficacy of Oxitard capsule and Immusante tablet in early stages of Oral Submucous Fibrosis- A randomized controlled trial.

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/09/036499
Enrollment
32
Registered
2021-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Immusante Tablet (Himalaya Drugs): 2 tablets twice daily before food (once in morning and evening) for 3 months with water. Control Intervention1: Oxitard capsules (Himalaya Drugs): 2 c

Sponsors

Dr D Y Patil Dental College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patients who are ready to quit the habit of tobacco chewing and accepted for regular follow ups. 2)Patients with early stages of Oral submucous fibrosis diagnosed clinically and functionally according early stages of Chandramani More et al (2011) classification: Early clinical/functional staging consist of: Clinical staging: Stage 1(S1):Stomatitis and/or blanching of oral mucosa Stage 2(S2): Presence of palpable fibrous bands in buccal mucosa and/or oropharynx, with/without stomatitis. Functional staging: M1: Interincisal mouth opening up to or greater than 35 mm. M2: Interincisal mouth opening between 25 and 35 mm 4)Patients who had not undergone any treatment earlier for oral submucous fibrosis.

Exclusion criteria

Exclusion criteria: 1)Patients who did not give their consent for participation. 2)Patients with any other oral lesions/conditions other than Oral submucous Fibrosis. 3)Pregnant women and Lactating mothers. 4) Any history of allergy/adverse reaction to similar pharmaceutical products, its components or ingredients.

Design outcomes

Primary

MeasureTime frame
1.Improvement in burning sensation, difficulty in speaking and eating will be recorded using VAS(Visual Analog Scale) 2. Improvement in mouth opening will be measured with a geometric scale. 3.Improvement in tongue protrusion will be assessed in units of a millimeter. 4.Improvement in cheek flexibility will be recorded in mm using technique previously published by Reddy et al 2011. 5.Improvement in gingival health will be evaluated using plaque index and gingival index. Timepoint: Baseline, At the end of 1month, At the end of 3month

Secondary

MeasureTime frame
NoneTimepoint: 0

Countries

India

Contacts

Public ContactDr Sahana Hegde Shetiya

Dr D Y Patil Dental college and Hospital

anmol.mathur@dpu.edu.in9899963523

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026